Your browser doesn't support javascript.
loading
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Buteau, James P; Martin, Andrew J; Emmett, Louise; Iravani, Amir; Sandhu, Shahneen; Joshua, Anthony M; Francis, Roslyn J; Zhang, Alison Y; Scott, Andrew M; Lee, Sze-Ting; Azad, Arun A; McJannett, Margaret M; Stockler, Martin R; Williams, Scott G; Davis, Ian D; Hofman, Michael S.
Afiliación
  • Buteau JP; Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Martin AJ; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia.
  • Emmett L; Department of Theranostics and Nuclear Medicine, St Vincent's Hospital, Sydney, NSW, Australia; Faculty of Medicine, UNSW Sydney, Sydney, NSW, Australia.
  • Iravani A; Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Sandhu S; Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Joshua AM; Department of Medical Oncology, Kinghorn Cancer Centre, St Vincent's Hospital, Sydney, NSW, Australia; School of Clinical Medicine, UNSW Sydney, Sydney, NSW, Australia.
  • Francis RJ; Department of Nuclear Medicine, Sir Charles Gairdner Hospital, Perth, WA, Australia; Medical School, University of Western Australia, Perth, WA, Australia.
  • Zhang AY; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Macquarie University Hospital, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
  • Scott AM; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC,
  • Lee ST; Department of Medicine, University of Melbourne, Melbourne, VIC, Australia; Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC,
  • Azad AA; Department of Medical Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • McJannett MM; Australian and New Zealand Urogenital and Prostate Cancer Trials Group, Sydney, NSW, Australia.
  • Stockler MR; NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.
  • Williams SG; Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia.
  • Davis ID; Eastern Health Clinical School, Monash University, Melbourne, VIC, Australia; Eastern Health, Melbourne, VIC, Australia.
  • Hofman MS; Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia. Electronic address: michael.hof
Lancet Oncol ; 23(11): 1389-1397, 2022 Nov.
Article en En | MEDLINE | ID: mdl-36261050
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antígeno Prostático Específico / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Humans / Male País/Región como asunto: Oceania Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Australia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Antígeno Prostático Específico / Neoplasias de la Próstata Resistentes a la Castración Tipo de estudio: Clinical_trials / Guideline / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Humans / Male País/Región como asunto: Oceania Idioma: En Revista: Lancet Oncol Asunto de la revista: NEOPLASIAS Año: 2022 Tipo del documento: Article País de afiliación: Australia